Safety and Efficacy of Polyvinyl Alcohol Sodium Acrylate Embolization Microspheres for CRLM

Exclusion Criteria

• •1. Patients with known severe allergy to contrast agents (iodine contrast agents, gadolinium contrast agents, etc.) or embolic materials (polyvinyl alcohol sodium acrylate copolymer) ;
• •2. White blood cell count\<3.0×109/L, platelet count\<75×109/L，hemoglobin\<70 g/L；
• •3. Total bilirubin\>2 times the upper limit of normal value, Alanine transaminase (ALT) or aspartate aminotransferase (AST) \>5 times the upper limit of normal value, Alkaline phosphatase\>2.5 times the upper limit of normal value, albumin\<30 g/L;
• •4. Creatinine\>1.5 times the upper limit of normal value, creatinine clearance rate\<30 mL/min;
• •5. Prothrombin time and activated partial thromboplastin time\>1.5 times the upper limit of normal value;
• •6. Target lesion blood supply artery cannot undergo TACE treatment (the blood supply artery is too thin，vasospasm or suspected vasospasm，peripheral vascular resistance of the blood supply artery hinders the entry of embolic microspheres into the lesion site，severe Atherosclerosis, etc) or there is a risk of embolism (collateral vascular pathway endangers normal areas, etc)；
• •7. The expected survival time is less than 3 months;
• •8. Patients who have received embolization therapy for the target lesion or undergo the first TACE treatment for the target lesion after enrollment and require combined ablation/radiotherapy;
• •9. Pregnant and lactating women, or those who plan to conceive during the study period;
• •10. Those who have participated in other intervention clinical trials within one month before the trial;
• •11. The researchers believe that the subjects are intolerant and other unsuitable candidates for participating in this clinical trial.